Ambev boosts capital via stock option exercises
Ambev S.A. approved a small capital increase after beneficiaries exercised stock options under its 2026 stock option program, part of the Stock Option Plan first approved on July 30, 2013.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ambev S.A. approved a small capital increase after beneficiaries exercised stock options under its 2026 stock option program, part of the Stock Option Plan first approved on July 30, 2013. The Board authorized the issuance of 2,026,133 new common shares with no par value.
The capital increase amounts to BRL 33,127,274.55, bringing total capital stock to BRL 58,308,213,544.96. The company reports potential dilution of 0.012855% based on the number of shares and 0.056846% relative to capital stock, indicating a very limited impact on existing shareholders.
Key Figures
Key Terms
Stock Option Plan financial
capital increase financial
potential dilution percentage financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What capital increase did Ambev (ABEV) approve in this Form 6-K?
What is Ambev’s new total capital stock after this increase?
When was Ambev’s Stock Option Plan originally approved?
Who approved and homologated Ambev’s capital increase?
AI-generated analysis. How Rhea-AI works. Not financial advice.